Related Experiment Videos
Adalimumab for treating rheumatoid arthritis
F Navarro-Sarabia1, R Ariza-Ariza, B Hernandez-Cruz
1Rheumatology, Hospital Universitario Virgen Macarena, Dr Fedriani, 3, Seville, Spain, 41009. federiconavarro@supercable.es
The Cochrane Database of Systematic Reviews
|July 22, 2005
Summary
Adalimumab (fully human anti-TNFalpha monoclonal antibody) is effective and safe for rheumatoid arthritis (RA) treatment, particularly when combined with methotrexate. It also slows radiographic progression in RA patients.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Adalimumab is a fully human anti-TNFalpha monoclonal antibody.
- Published studies suggest Adalimumab is effective and safe for Rheumatoid Arthritis (RA).
Purpose of the Study:
- To assess the efficacy and safety of Adalimumab in treating RA.
- To evaluate Adalimumab's impact on radiographic progression in RA patients.
Main Methods:
- Systematic review of RCTs and CCTs up to August 2004.
- Searched MEDLINE, CINAHL, EBM Reviews, Health STAR, and conference proceedings.
- Data extraction and quality assessment by two independent reviewers; pooled data where heterogeneity was absent.
Main Results:
- Adalimumab (40 mg every other week) plus DMARDs significantly improved ACR 20/50/70 responses at 24 and 52 weeks.
- Adalimumab slowed radiographic progression at 52 weeks.
- Adalimumab monotherapy showed efficacy but with a smaller effect size compared to combination therapy.
Conclusions:
- Adalimumab in combination with methotrexate is efficacious and safe for RA treatment.
- Adalimumab slows radiographic progression in RA patients.
- Adalimumab monotherapy is also efficacious and safe, though less effective than combination therapy.